The 50-patient, randomized, controlled, open-label trial aimed to explore the use of the Pico system use prophylactically in patients undergoing major abdominal surgery, the company said.
Data from the trial indicated that 30-days post operation, SSI incidence rate was reduced by 74% for patients treated with the NICO single use NPWT system compared to those treated with standard care. Patients treated with NICO also had hospital stay time reduced by approximately 8 days, the company said.
“This study underscores the importance of PICO single use NPWT in treating patients who have undergone a laparotomy. As surgeons, we are always looking for effective and cost efficient ways to treat patients, and this study demonstrates that PICO single use NPWT can significantly reduce both the incidence of surgical site infection and the length of stay, resulting in a potential reduction in healthcare costs,” Colin Peirce of Limerick, Ireland’s University Hospital said in a prepared statement.
“This study is the latest addition of research that reinforces the importance of PICO Single Use NPWT and the significant impact it has on reducing SSIs, healthcare costs and ultimately improving the patient’s quality of life. It follows the recent release of global guidelines from the World Health Organization recommending the use of NPWT prophylactically,” chief medical officer Andy Weymann said in a press release.
Last September, Smith & Nephew released results from a trial of its Pico system used in orthopedic surgeries, touting reductions in wound exudate distributions, dressing changes and hospital stays.